Inventor · disambiguated record
Jianqing Xu
Also filed as: XU JIANQING
20 granted patents·27 pending applications·42 citations·filing 2000–2025
91Inventor score
Files withWUXI BIOLOGICS IRELAND LTD12SHANGHAI SINOBAY BIOTECHNOLOGY CO LTD6CSTONE PHARMACEUTICALS3FORD GLOBAL TECH LLC3SHANGHAI PUBLIC HEALTH CLINICAL CT3
Top patents by PatentIndex Score
47 records- 0195US11078281B2Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)WUXI BIOLOGICS SHANGHAI CO LTD·Filed 2020·Granted Aug 3, 2021·8 cites·7 claims
- 0286US11845796B2Bispecific polypeptide complexesWUXI BIOLOGICS IRELAND LTD·Filed 2018·Granted Dec 19, 2023·2 cites·27 claims
- 0384US12240906B2Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)WUXI BIOLOGICS SHANGHAI CO LTD·Filed 2023·Granted Mar 4, 2025·0 cites·6 claims
- 0483US11643463B2Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)WUXI BIOLOGIES SHANGHAI CO LTD·Filed 2017·Granted May 9, 2023·3 cites·4 claims
- 0582USD914301SPet braceXU JIANQING·Filed 2019·Granted Mar 23, 2021·24 cites·1 claims
- 0674US2024124586A1Novel bispecific polypeptide complexesWUXI BIOLOGICS IRELAND LTD·Filed 2023·Application pending·0 cites
- 0773US2024101676A1The novel monoclonal antibodies to programmed death 1 (pd-1)CSTONE PHARMACEUTICALS·Filed 2023·Application pending·0 cites
- 0872US11414487B2Monoclonal antibodies to programmed death 1 (PD-1)CSTONE PHARMACEUTICALS·Filed 2016·Granted Aug 16, 2022·1 cites·18 claims
- 0972US7196186B2DNA composition and uses thereofRES INST FOR GENETIC AND HUMAN·Filed 2004·Granted Mar 27, 2007·3 cites·2 claims
- 1072US2025163156A1Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)WUXI BIOLOGICS SHANGHAI CO LTD·Filed 2025·Application pending·0 cites
- 1170US11833888B2Method and system for protecting against low refrigerant charge in electrified vehicleFORD GLOBAL TECH LLC·Filed 2022·Granted Dec 5, 2023·0 cites·14 claims
- 1270US10457118B2Vehicle and vehicle cooling systemFORD GLOBAL TECH LLC·Filed 2017·Granted Oct 29, 2019·1 cites·19 claims
- 1368US2025391200A1Iris feature acquisition and object identificationTENCENT TECH SHENZHEN CO LTD·Filed 2025·Application pending·0 cites
- 1467US2023014722A1Novel Monoclonal Antibodies to Programmed DEATH (PD-1)CSTONE PHARMACEUTICALS·Filed 2022·Application pending·0 cites
- 1564US2008234215A1DNA composition and uses thereofLISZIEWICZ JULIANNA·Filed 2007·Application pending·0 cites
- 1662US11352411B2Fusion peptides of CD4 helper T cell epitopes and vaccines thereofVACDIAGN BIOTECHNOLOGY CO LTD·Filed 2018·Granted Jun 7, 2022·0 cites·31 claims
- 1762US2025145679A1Heterodimeric polypeptide complexes comprising il-15 variants and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2023·Application pending·0 cites
- 1862US2024368279A1Antibody Specifically Binding to CD47, Recombinant Oncolytic Virus Thereof and Use ThereofSHANGHAI SINOBAY BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 1961US12195517B2Recombinant viral vector, immune composition containing same, and use thereofVACDIAGN BIOTECHNOLOGY CO LTD·Filed 2019·Granted Jan 14, 2025·0 cites·12 claims
- 2061US2025368708A1TREFOIL FACTOR 2/INTERFERON alpha2 FUSION PROTEIN AND APPLICATION THEREOF IN PREVENTION AND TREATMENT OF VIRAL INFECTIOUS DISEASESUNIV FUDAN·Filed 2022·Application pending·0 cites
- 2161US2025000946A1Il-2 variants and fusion proteins thereofWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 2260US2023008090A1A novel anti-cd3/anti-egfr bispecific antibody and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2020·Application pending·0 cites
- 2359US12239699B2Immunogen for broad-spectrum influenza vaccine and application thereofSHANGHAI PUBLIC HEALTH CLINICAL CT·Filed 2018·Granted Mar 4, 2025·0 cites·4 claims
- 2458US2025319126A1Condition-controlled spliceable chimeric antigen receptor molecule and application thereofSHANGHAI SINOBAY BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 2558US2025297002A1Bispecific t-cell engager, recombinant oncolytic virus thereof, and use thereofSHANGHAI SINOBAY BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 2658US2024343767A1Hypoxia-Triggered Artificial Transcription Factor, a Hypoxia-Triggered Transcription Control System and Use ThereofSHANGHAI SINOBAY BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 2758US2024317872A1Polypeptide complexes with improved stability and expressionWUXI BIOLOGICS IRELAND LTD·Filed 2022·Application pending·0 cites
- 2856US2025215109A1Anti-her2/anti-cd47 molecules and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2023·Application pending·0 cites
- 2956US2025019446A1Antibody Targeting Axl Protein and Antigen Binding Fragment Thereof, and Preparation Method Therefor and Application ThereofSHANGHAI SINOBAY BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 3055US2024076411A1Multispecific antigen binding proteinsWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 3154US11816880B2Face recognition method and apparatus, computer device, and storage mediumTENCENT TECH SHENZHEN CO LTD·Filed 2022·Granted Nov 14, 2023·0 cites·20 claims
- 3254US2023270823A1Long-acting il-15 and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2021·Application pending·0 cites
- 3352US10543731B2Auxiliary HVAC system for a vehicleFORD GLOBAL TECH LLC·Filed 2013·Granted Jan 28, 2020·0 cites·7 claims
- 3451US2022177839A1Composition, culture medium and method for inducing and/or amplifying tscm in vitroSHANGHAI SINOBAY BIOTECHNOLOGY CO LTD·Filed 2019·Application pending·0 cites
- 3550US12251434B2Target sequence of RNA virus and use thereofSHANGHAI PUBLIC HEALTH CLINICAL CT·Filed 2021·Granted Mar 18, 2025·0 cites·7 claims
- 3649US2022162312A1Novel bispecific cd3/cd20 polypeptide complexesWUXI BIOLOGICS IRELAND LTD·Filed 2020·Application pending·0 cites
- 3749US2023173028A1Application of TFF2 Protein and IFN-k Protein Combination in Treatment of a Novel Coronavirus InfectionSHANDONG RUIYING PIONEER PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 3848US2023135239A1Drug for treating severe acute respiratory syndrome caused by coronavirus and complications thereof and use of the drugSHANGHAI PUBLIC HEALTH CLINICAL CT·Filed 2021·Application pending·0 cites
- 3947US12508309B2Recombinant viral vector, immunogenic composition comprising same, and usesVACDIAGN BIOTECHNOLOGY CO LTD·Filed 2020·Granted Dec 30, 2025·0 cites·9 claims
- 4047US2021340252A1Anti-tim-3 antibodies and uses thereofWUXI BIOLOGICS IRELAND LTD·Filed 2019·Application pending·0 cites
- 4145US2003095988A1Method of inducing autovaccination against HIV infection using structured treatment interruptionsFiled 2000·Application pending·0 cites
- 4244US11365254B2Bispecific CD3/CD19 polypeptide complexesWUXI BIOLOGICS IRELAND LTD·Filed 2018·Granted Jun 21, 2022·0 cites·20 claims
- 4343US11773373B2Method for amplifying CD8+T cells and cell subpopulations thereof in-vitroSHANGHAI INNOVATIVE CHANGAN BIOLOGICAL TECH CO LTD·Filed 2017·Granted Oct 3, 2023·0 cites·7 claims
- 4442US2021388065A1Antibodies to sars-coronavirus (covid-19) s1 spike proteinACTIVE MOTIF SHANGHAI LTD·Filed 2020·Application pending·0 cites
- 4537US9504741B2Immune methods against influenza viruses and combinatorial vaccines thereofXU JIANQING·Filed 2011·Granted Nov 29, 2016·0 cites·14 claims
- 4635US11447746B2Method for inducing amplification of type I NKT cells in vitroSHANGHAI INNOVATIVE CHANGAN BIOLOGICAL TECH CO LTD·Filed 2017·Granted Sep 20, 2022·0 cites·9 claims
- 4730US2016272706A1Il-13 binding proteins and uses thereofMEDIMMUNE LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jianqing Xu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →